• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

乳腺导管原位癌中G1/S调节蛋白的组织芯片分析表明,细胞周期蛋白D1水平低与局部复发相关。

Tissue microarray analyses of G1/S-regulatory proteins in ductal carcinoma in situ of the breast indicate that low cyclin D1 is associated with local recurrence.

作者信息

Jirström K, Ringberg A, Fernö M, Anagnostaki L, Landberg G

机构信息

Department of Laboratory Medicine, Lund University, Malmö University Hospital, S-205 02, Malmö, Sweden.

出版信息

Br J Cancer. 2003 Nov 17;89(10):1920-6. doi: 10.1038/sj.bjc.6601398.

DOI:10.1038/sj.bjc.6601398
PMID:14612904
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC2394433/
Abstract

Ductal carcinoma in situ (DCIS) of the breast constitutes about 10% of all diagnosed breast cancers and, despite surgical removal, it may recur, either as DCIS or invasive breast cancer. Nuclear grade and growth pattern according to Andersen et al as well as surgical margins are factors that have been used to predict local recurrence, but ideally a set of tumour-specific factors should be identified and used as prognostic markers. Many cell cycle regulatory gene products have been shown to be involved in the formation of tumours and are either oncogenes or suppressor genes and involved in key processes in the transformation. We therefore characterised the cell cycle regulators cyclin E, cyclin D1, p27 and p16 in a material of DCIS cases arranged in a tissue microarray. With a manual tissue arrayer, 52% of the initial 177 DCIS samples were successfully targeted allowing immunohistochemical analyses of all four proteins in 92 cases of DCIS. As also observed in invasive breast cancer, there was a trend indicating that DCIS cases with high cyclin D1 were cyclin E low and oestrogen receptor-positive, whereas cyclin E high DCIS cases were cyclin D1 low and oestrogen receptor-negative. For the 64 patients that did not receive postoperative radiotherapy, there were 16 local recurrences (eight DCIS and eight invasive breast cancer) during a mean follow-up time of 63 months. Cyclin E, p27 or p16 were not associated with local recurrence, but interestingly cyclin D1 was significantly and inversely associated with local recurrence, both using univariate and multivariate analyses. In summary, using a tissue array approach we have shown that cyclin D1, besides growth pattern, is a prognostic marker for local recurrence in DCIS.

摘要

乳腺导管原位癌(DCIS)约占所有确诊乳腺癌的10%,尽管已手术切除,但仍可能复发,复发形式可为DCIS或浸润性乳腺癌。Andersen等人提出的核分级和生长模式以及手术切缘是用于预测局部复发的因素,但理想情况下,应确定一组肿瘤特异性因素并将其用作预后标志物。许多细胞周期调节基因产物已被证明参与肿瘤形成,它们要么是癌基因,要么是抑癌基因,参与细胞转化的关键过程。因此,我们在组织微阵列中排列的DCIS病例材料中对细胞周期调节因子细胞周期蛋白E、细胞周期蛋白D1、p27和p16进行了特征分析。使用手动组织阵列仪,最初177个DCIS样本中有52%被成功定位,从而能够对92例DCIS病例中的所有四种蛋白质进行免疫组织化学分析。正如在浸润性乳腺癌中也观察到的那样,有一种趋势表明,细胞周期蛋白D1高的DCIS病例细胞周期蛋白E低且雌激素受体阳性,而细胞周期蛋白E高的DCIS病例细胞周期蛋白D1低且雌激素受体阴性。对于64例未接受术后放疗的患者,在平均63个月的随访期内有16例局部复发(8例DCIS和8例浸润性乳腺癌)。细胞周期蛋白E、p27或p16与局部复发无关,但有趣的是,无论是单因素分析还是多因素分析,细胞周期蛋白D1均与局部复发显著负相关。总之,使用组织阵列方法我们已经表明,除生长模式外,细胞周期蛋白D1是DCIS局部复发的预后标志物。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1538/2394433/c06955ceeac5/89-6601398f4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1538/2394433/1f6e50c2d480/89-6601398f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1538/2394433/f1168c7f8f56/89-6601398f2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1538/2394433/788a2ce5fab7/89-6601398f3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1538/2394433/c06955ceeac5/89-6601398f4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1538/2394433/1f6e50c2d480/89-6601398f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1538/2394433/f1168c7f8f56/89-6601398f2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1538/2394433/788a2ce5fab7/89-6601398f3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1538/2394433/c06955ceeac5/89-6601398f4.jpg

相似文献

1
Tissue microarray analyses of G1/S-regulatory proteins in ductal carcinoma in situ of the breast indicate that low cyclin D1 is associated with local recurrence.乳腺导管原位癌中G1/S调节蛋白的组织芯片分析表明,细胞周期蛋白D1水平低与局部复发相关。
Br J Cancer. 2003 Nov 17;89(10):1920-6. doi: 10.1038/sj.bjc.6601398.
2
Expression of p21Waf1, p27Kip1 and cyclin D1 proteins in breast ductal carcinoma in situ: Relation with clinicopathologic characteristics and with p53 expression and estrogen receptor status.p21Waf1、p27Kip1和细胞周期蛋白D1蛋白在乳腺导管原位癌中的表达:与临床病理特征、p53表达及雌激素受体状态的关系。
Pathol Int. 2001 Feb;51(2):94-9. doi: 10.1046/j.1440-1827.2001.01173.x.
3
Histological type and marker expression of the primary tumour compared with its local recurrence after breast-conserving therapy for ductal carcinoma in situ.导管原位癌保乳治疗后原发性肿瘤与其局部复发的组织学类型和标志物表达比较。
Br J Cancer. 2001 Feb;84(4):539-44. doi: 10.1054/bjoc.2000.1618.
4
S100A7 (psoriasin) expression is associated with aggressive features and alteration of Jab1 in ductal carcinoma in situ of the breast.S100A7(牛皮癣素)的表达与乳腺导管原位癌的侵袭性特征及Jab1的改变相关。
Breast Cancer Res. 2004;6(4):R308-15. doi: 10.1186/bcr791. Epub 2004 Apr 26.
5
EGFR, HER-2/neu, cyclin D1, p21 and p53 in correlation to cell proliferation and steroid hormone receptor status in ductal carcinoma in situ of the breast.乳腺导管原位癌中表皮生长因子受体(EGFR)、人表皮生长因子受体2/神经(HER-2/neu)、细胞周期蛋白D1、p21和p53与细胞增殖及类固醇激素受体状态的相关性
Breast Cancer Res Treat. 2003 May;79(2):187-98. doi: 10.1023/a:1023958324448.
6
Loss of the expression of the tumor suppressor gene ARHI is associated with progression of breast cancer.抑癌基因ARHI表达缺失与乳腺癌进展相关。
Clin Cancer Res. 2003 Sep 1;9(10 Pt 1):3660-6.
7
Her2 and Ki67 Biomarkers Predict Recurrence of Ductal Carcinoma in Situ.Her2和Ki67生物标志物可预测导管原位癌的复发。
Appl Immunohistochem Mol Morphol. 2016 Jan;24(1):20-5. doi: 10.1097/PAI.0000000000000223.
8
p27KIP-1, cyclin A and cyclin D1 protein expression in ductal carcinoma in situ of the breast: p27KIP-1 correlates with hormone receptor status but not with local recurrence.p27KIP-1、细胞周期蛋白A和细胞周期蛋白D1在乳腺导管原位癌中的蛋白表达:p27KIP-1与激素受体状态相关,但与局部复发无关。
Pathol Int. 2007 Apr;57(4):183-9. doi: 10.1111/j.1440-1827.2007.02079.x.
9
Biomarker expression and risk of subsequent tumors after initial ductal carcinoma in situ diagnosis.初始导管原位癌诊断后生物标志物表达与后续肿瘤风险。
J Natl Cancer Inst. 2010 May 5;102(9):627-37. doi: 10.1093/jnci/djq101. Epub 2010 Apr 28.
10
Association of different patterns of expression of beta-catenin and cyclin D1 with pathogenesis of breast carcinoma.β-连环蛋白和细胞周期蛋白D1不同表达模式与乳腺癌发病机制的关联
Indian J Pathol Microbiol. 2020 Jan-Mar;63(1):13-18. doi: 10.4103/IJPM.IJPM_419_19.

引用本文的文献

1
Subtype-Specific Tumour Immune Microenvironment in Risk of Recurrence of Ductal Carcinoma In Situ: Prognostic Value of HER2.导管原位癌复发风险中的亚型特异性肿瘤免疫微环境:HER2的预后价值
Biomedicines. 2022 May 3;10(5):1061. doi: 10.3390/biomedicines10051061.
2
Breast cancer with neoductgenesis: histopathological criteria and its correlation with mammographic and tumour features.伴有新导管生成的乳腺癌:组织病理学标准及其与乳腺X线摄影和肿瘤特征的相关性。
Int J Breast Cancer. 2014;2014:581706. doi: 10.1155/2014/581706. Epub 2014 Oct 8.
3
A Comparison of Tumor Biology in Primary Ductal Carcinoma In Situ Recurring as Invasive Carcinoma versus a New In Situ.

本文引用的文献

1
Cdk4/cyclin D1 kinase, a universal and critical regulator of apoptosis.细胞周期蛋白依赖性激酶4/细胞周期蛋白D1激酶,一种普遍且关键的细胞凋亡调节因子。
Anticancer Res. 2003 Jan-Feb;23(1A):235-43.
2
Value of the Van Nuys Prognostic Index in prediction of recurrence of ductal carcinoma in situ after breast-conserving surgery.范努伊斯预后指数在保乳手术后导管原位癌复发预测中的价值。
Br J Surg. 2003 Apr;90(4):426-32. doi: 10.1002/bjs.4051.
3
Prognostic value of combined analysis of cyclin D1 and estrogen receptor status in breast cancer patients.
原发性导管原位癌复发为浸润性癌与新发原位癌的肿瘤生物学比较
Int J Breast Cancer. 2013;2013:582134. doi: 10.1155/2013/582134. Epub 2013 Dec 29.
4
Progesterone receptor assembly of a transcriptional complex along with activator protein 1, signal transducer and activator of transcription 3 and ErbB-2 governs breast cancer growth and predicts response to endocrine therapy.孕激素受体与激活蛋白1、信号转导和转录激活因子3以及ErbB-2共同组装转录复合物,调控乳腺癌生长并预测内分泌治疗反应。
Breast Cancer Res. 2013 Dec 17;15(6):R118. doi: 10.1186/bcr3587.
5
Biological Markers Predictive of Invasive Recurrence in DCIS.预测导管原位癌侵袭性复发的生物标志物
Clin Med Oncol. 2008;2:7-18. Epub 2008 Jan 22.
6
Biological Markers in DCIS and Risk of Breast Recurrence: A Systematic Review.DCIS 中的生物学标志物与乳腺癌复发风险:系统评价。
J Cancer. 2011 May 1;2:232-61. doi: 10.7150/jca.2.232.
7
Long-term survival of women with basal-like ductal carcinoma in situ of the breast: a population-based cohort study.基于人群的队列研究:乳腺基底样导管原位癌女性的长期生存。
BMC Cancer. 2010 Nov 30;10:653. doi: 10.1186/1471-2407-10-653.
8
Cyclin E deregulation is an early event in the development of breast cancer.细胞周期蛋白E失调是乳腺癌发展过程中的早期事件。
Breast Cancer Res Treat. 2009 Jun;115(3):651-9. doi: 10.1007/s10549-008-0266-0. Epub 2008 Dec 24.
9
COX-2 and PPARgamma expression are potential markers of recurrence risk in mammary duct carcinoma in-situ.环氧化酶-2(COX-2)和过氧化物酶体增殖物激活受体γ(PPARγ)的表达是乳腺导管原位癌复发风险的潜在标志物。
BMC Cancer. 2008 Jan 31;8:36. doi: 10.1186/1471-2407-8-36.
10
Abrogated response to cellular stress identifies DCIS associated with subsequent tumor events and defines basal-like breast tumors.对细胞应激反应的缺失可识别与后续肿瘤事件相关的导管原位癌,并定义基底样乳腺癌。
Cancer Cell. 2007 Nov;12(5):479-91. doi: 10.1016/j.ccr.2007.10.017.
细胞周期蛋白D1与雌激素受体状态联合分析在乳腺癌患者中的预后价值。
Pathol Int. 2003 Feb;53(2):74-80. doi: 10.1046/j.1440-1827.2003.01441.x.
4
Constitutive overexpression of cyclin D1 but not cyclin E confers acute resistance to antiestrogens in T-47D breast cancer cells.细胞周期蛋白D1的组成型过表达而非细胞周期蛋白E的过表达赋予T-47D乳腺癌细胞对抗雌激素的急性抗性。
Cancer Res. 2002 Dec 1;62(23):6916-23.
5
Involvement of G1/S cyclins in estrogen-independent proliferation of estrogen receptor-positive breast cancer cells.G1/S 细胞周期蛋白参与雌激素受体阳性乳腺癌细胞的非雌激素依赖性增殖。
Oncogene. 2002 Nov 21;21(53):8158-65. doi: 10.1038/sj.onc.1206012.
6
Detection of ductal carcinoma in situ in women undergoing screening mammography.在接受乳腺钼靶筛查的女性中检测导管原位癌。
J Natl Cancer Inst. 2002 Oct 16;94(20):1546-54. doi: 10.1093/jnci/94.20.1546.
7
The cyclin D1 high and cyclin E high subgroups of breast cancer: separate pathways in tumorogenesis based on pattern of genetic aberrations and inactivation of the pRb node.乳腺癌的细胞周期蛋白D1高表达和细胞周期蛋白E高表达亚组:基于基因畸变模式和视网膜母细胞瘤蛋白节点失活的肿瘤发生的不同途径。
Oncogene. 2002 Jul 11;21(30):4680-90. doi: 10.1038/sj.onc.1205578.
8
Cyclin D1 and mammary carcinoma: new insights from transgenic mouse models.细胞周期蛋白D1与乳腺癌:转基因小鼠模型带来的新见解
Breast Cancer Res. 2002;4(1):14-7. doi: 10.1186/bcr411. Epub 2001 Nov 30.
9
Cell biological factors in ductal carcinoma in situ (DCIS) of the breast-relationship to ipsilateral local recurrence and histopathological characteristics.乳腺导管原位癌(DCIS)中的细胞生物学因素——与同侧局部复发及组织病理学特征的关系
Eur J Cancer. 2001 Aug;37(12):1514-22. doi: 10.1016/s0959-8049(01)00165-4.
10
Expression of p21Waf1, p27Kip1 and cyclin D1 proteins in breast ductal carcinoma in situ: Relation with clinicopathologic characteristics and with p53 expression and estrogen receptor status.p21Waf1、p27Kip1和细胞周期蛋白D1蛋白在乳腺导管原位癌中的表达:与临床病理特征、p53表达及雌激素受体状态的关系。
Pathol Int. 2001 Feb;51(2):94-9. doi: 10.1046/j.1440-1827.2001.01173.x.